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Abstract The roots of licorice (Glycyrrhiza glabra) are a
rich source of flavonoids, in particular, prenylated flavo-
noids, such as the isoflavan glabridin and the isoflavene
glabrene. Fractionation of an ethyl acetate extract from
licorice root by centrifugal partitioning chromatography
yielded 51 fractions, which were characterized by liquid
chromatography–mass spectrometry and screened for ac-
tivity in yeast estrogen bioassays. One third of the fractions
displayed estrogenic activity towards either one or both
estrogen receptors (ERs; ERα and ERβ). Glabrene-rich
fractions displayed an estrogenic response, predominantly
to the ERα. Surprisingly, glabridin did not exert agonistic
activity to both ER subtypes. Several fractions displayed
higher responses than the maximum response obtained with
the reference compound, the natural hormone 17β-estradiol
(E2). The estrogenic activities of all fractions, including
this so-called superinduction, were clearly ER-mediated,
as the estrogenic response was inhibited by 20–60% by
known ER antagonists, and no activity was found in yeast
cells that did not express the ERα or ERβ subtype.
Prolonged exposure of the yeast to the estrogenic
fractions that showed superinduction did, contrary to
E2, not result in a decrease of the fluorescent response.
Therefore, the superinduction was most likely the result
of stabilization of the ER, yeast-enhanced green fluores-
cent protein, or a combination of both. Most fractions
displaying superinduction were rich in flavonoids with
single prenylation. Glabridin displayed ERα-selective
antagonism, similar to the ERα-selective antagonist RU
58668. Whereas glabridin was able to reduce the
estrogenic response of E2 by approximately 80% at 6×
10
−6 M, glabrene-rich fractions only exhibited agonistic




Flavonoids are a broad class of phenolic compounds mainly
found in plants with a wide range of bioactivities [1].
Prenylated flavonoids, in particular, are of interest with
respecttobioactivity,asprenylationisconsideredtomodulate
the responses towards the estrogen receptor [1, 2]. Prenyl-
substitution of the flavonoid subclasses flavones, flavanones,
and flavonols has been linked to an increased affinity to the
estrogen receptor α (ERα)[ 3–5], e.g., prenylation of the
eight-position of the flavanone naringenin results in a 200–
1,000 higher estrogenic activity [6]. Furthermore, the
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DOI 10.1007/s00216-011-5061-9prenylation of isoflavonoids has been suggested to induce
antagonistic activity when binding to ERα [5, 7, 8].
Licorice roots (Glycyrrhiza glabra) are a rich source of
prenylated flavonoids. They might offer opportunities for
the development of new food supplements related to, e.g.,
the alleviation of osteoporosis and menopausal complaints
[9]. Approximately 75 prenylated flavonoids have been
identified, mainly belonging to isoflavans, isoflavenes, and
flavanones [10, 11].
Previous studies have shown that licorice root extracts
have estrogenic activity towards the ERα and ERβ [12,
13]. The key estrogenic compounds isolated from G. glabra
were identified as glabrene and glabridin, both prenylated
isoflavonoids [14, 15]. The estrogen-like activities of both
compounds have been established by means of competitive
ligand binding assays, in vitro cell assays, and in vivo
animal models [16, 17]. It has been demonstrated that
glabrene and glabridin bind to the ER with EC50 values of
5×10
−5 M and 5×10
−6 M, respectively. These values were
obtained using an MCF-7 cell line that is known to express
the ERα type mainly (no detectable ERβ amounts on the
protein level), indicating that both compounds were
agonists [18, 19]. However, the specific estrogenic poten-
cies of glabrene and glabridin towards ERα and ERβ and
their potential antagonistic activities have not yet been
investigated. Such information is vital for understanding
their specific estrogenic activity in the human body.
The aim of the present study was to determine the
predominant estrogenic compounds of licorice roots that are
active on both ER subtypes and investigate their agonistic
and antagonistic potencies. To this end, fractions of a
licorice root extract obtained by centrifugal partitioning
chromatography were characterized by liquid
chromatography-mass spectrometry (LC-MS) and subse-
quently screened for (anti)estrogenic activity using yeast
estrogen bioassays.
Experimental section
Materials The roots of G. glabra, collected in Afghanistan,
were provided by Frutarom US (North Bergen, NJ, USA).
Estradiol was purchased from Sigma Aldrich (St. Louis,
MO, USA) and glabridin from Wako Chemicals GmbH
(Neuss, Germany). RU 58668 and R,R-diethyl-THC (R,R-
THC) were purchased from Tocris Bioscience (Bristol,
UK). Analytical reagent-grade n-hexane, acetone, and abso-
lute ethanol and ultra-LC-MS grade acetonitrile were pur-
chased from Biosolve BV (Valkenswaard, The Netherlands).
Water was prepared using a Milli-Q water purification system
(Millipore, Billerica, MA, USA). Dimethylsulfoxide (DMSO)
and all other chemicals were purchased from Merck
(Darmstadt, Germany).
Preparation of licorice extract The roots were milled with
a ZM 200 Retsch Ultra Centrifugal Mill (Haan, Germany)
using a 1-mm sieve. The root powder was extracted with
ethyl acetate (EA) in a ratio of 1 to 25 (w/w) for 2 h at 40 °C
under continuous stirring. The extract was obtained by
pressing the mixture with a Fischer Maschinenbau hydraulic
press type HP 5M (Gemmrigheim, Germany) under 40 bar
for 1 h. The dried extract was obtained after evaporation of
the EA under reduced pressure at 40 °C.
CPC fractionation of licorice extract Centrifugal partition-
ing chromatography (CPC) was performed using a thermo-
stated Kromaton FCPC machine (Angers, France)
connected to an Armen AP 100 (Chromtech, Boronia,
VIC, Australia) plunger pump. The two-phase solvent
system used consisted of n-hexane/acetone/water in a ratio
of 5:9:1 (v/v/v). It was equilibrated under stirring at 22 °C
for at least 1 h. Small-scale fractionations as part of the
method development were done with a 200-mL rotor in
ascending mode (i.e., lower phase is stationary phase) at
22 °C, a rotation speed of 1,000 rpm, and a flow rate of
10 mL/min. The volume of displaced stationary phase was
approximately 83 mL. Eighty-five milligrams dried extract
was dissolved in a mixture of upper and lower phase, 4 mL
of each phase. The fractionation process was monitored
using a Jasco UV-2075 UV detector equipped with a 1-mm
preparative cell at a wavelength of 330 nm (absorbance is
expressed as relative response to the highest peak).
For the actual fractionation of the licorice root extract, a
1,000-mL rotor was used (22 °C; rotation speed 1,100 rpm;
flow rate 25 mL/min). The volume of displaced stationary
phase in the 1,000 mL rotor was approximately 625 mL. Seven
hundred fifty milligrams dried extract was dissolved in 28 mL
of a mixture of upper and lower phase (1:1). Seven subsequent
runs were performed that resulted in 51 fractions per run; the
fraction size was 50 mL. Based on the CPC UV profile,
corresponding fractions were combined and evaporated in
combination with lyophilization in order to remove solvents.
The combined fractions were resolubilized in absolute ethanol
(EtOH) and stored at −20 °C. All samples were thawed and
centrifuged before analysis. Fractions collected were analyzed
by ultra-high performance liquid chromatography (UHPLC)-
mass spectrometry at a concentration of 1 mg/mL.
Reversed-phase UHPLC Samples were analyzed using an
Accela UHPLC system (Thermo Scientific, San Jose, CA,
USA) equipped with pump, autosampler, and PDA detector.
Samples (1 μL) were injected onto an Acquity UPLC BEH
C18 column (2.1×150 mm, 1.7 μm particle size) with an
Acquity UPLC BEH C18 Vanguard pre-column (2.1×
5 mm, 1.7 μm particle size; Waters, Milford, MA, USA).
Eluents were water-acidified with 0.1% (v/v) acetic acid
(eluent A) and acetonitrile-acidified with 0.1% (v/v) acetic
306 R. Simons et al.acid (eluent B). The flow rate was 300 μL/min, and the
PDA detector was set to measure at a range of 205–400 nm.
The following elution profile was used at 0–18 min, linear
gradient from 10–100% (v/v)B ;1 8 –22 min, isocratic on
100% B; 22–23 min, linear gradient from 100–10% B; and
23–25 min, isocratic on 10% B.
Electrospray ionization mass spectrometry (ESI-MS) Mass
spectrometric data were obtained by analyzing samples on
an ion trap LTQ-XL (Thermo Scientific) equipped with an
ESI-MS probe coupled to the reversed-phase UHPLC.
Helium was used as sheath gas and nitrogen as auxiliary
gas. Data were collected over an m/z-range of 150–1,500.
Data-dependent tandem mass spectrometry (MS
n) analysis
was performed with a normalized collision energy of 35%.
The MS
n fragmentation was always performed on the most
intense daughter ion in the MS
n−1 spectrum. Most settings
were optimized via automatic tuning using “Tune Plus”
(Xcalibur 2.0.7, Thermo Scientific). To this end, the system
was tuned with glabridin in both positive ionization and
negative ionization mode. In both modes, the ion transfer
tube temperature was 350 °C and the source voltage,
4.8 kV. Data acquisition and reprocessing were done with
Xcalibur 2.0.7. Mass spectral data interpretation and peak
determination were performed with Mass Frontier 5.0
(Highchem, Bratislava, Slovakia).
Determination of estrogenic activity The protocols for the
yeast estrogen bioassays were adopted from Bovee et al.
[20] with slight modifications. The genetically modified
yeast strains have a strong constitutive expression vector
stably integrated in the genome to express either the human
estrogen receptor α (ERα) or the human estrogen receptor
β (ERβ). The yeast genome also contains a reporter
construct. This reporter construct contains an inducible
yeast-enhanced green fluorescent protein (yEGFP) regulated
by the activation of a minimal promoter with estrogen-
responsive elements. Cultures of the yeast estrogen biosensor
witheitherERα or ERβ were grown overnight at 30 °C with
shaking at 200 rpm. At the late log phase, the cultures of both
estrogen receptors were diluted in the selective minimal
medium supplemented with either leucine (ERα) or histidine
(ERβ) to an optical density (OD) value (630 nm) of 0.05±
0.01 (ERα) and 0.15±0.05 (ERβ). For exposure, 200-μL
aliquots of these diluted yeast cultures were combined with
2 μL of test compound or extract (in various concentrations)
in a 96-well plate to test the agonistic properties of these
compounds. DMSO (blank) and control samples contain-
ing 17β-estradiol (E2) or genistein dissolved in DMSO
w e r ei n c l u d e di ne a c he x p e r i m ent. Dilution series of each
sample were prepared in DMSO, and the final concentra-
tion of DMSO in the assay did not exceed 1% (v/v). Each
sample concentration was assayed in triplicate. Exposure
was performed for 24 or 6 h for the ERα or ERβ assay,
respectively, at 30 °C and orbital shaking at 200 rpm.
Fluorescence and OD were measured at 0 and 24 h for
the ERα and 0 and 6–8 h for the ERβ in a Tecan Infinite
F500 (Männedorf, Switzerland), using an excitation filter of
485 nm (bandwidth, 20 nm) and an emission filter of
535 nm (bandwidth, 35 nm). The fluorescence signals of
the samples were corrected with the signal obtained with
the diluted yeast suspension at t 0 h (background signal). In
order to check the viability of the yeast in each well, the
absorbance was measured at 630 nm. Each fraction was
tested in a concentration series ranging from 0.1–100 μg/mL.
EC50 calculations were performed in Sigma Plot (8.02, SPSS
Inc.). In a number of cases, a concentration of 10 μg/mL for
the ERα and 3 μg/mL for the ERβ resulted in decreased
yeast growth during incubation of more than 50% during
incubation due to cytotoxicity. This cytotoxicity could be due
to the anti-microbial properties of licorice root constituents
as reported before [21, 22].
A dilution series of estradiol and genistein were used as
reference controls in this bioassay. The EC50 values in the
ERα bioassay were 0.86 nM and 1.73 μM for estradiol and
genistein, respectively, and 0.12 and 9.1 nM in the ERβ
bioassay, respectively. All EC50 values were in line with
those reported previously [20].
For the determination of ER antagonism, the yeast cells
were exposed to the EC70 (ERα) or the EC90 (ERβ)o f
estradiol in combination with different dilutions of a test
compound or fraction (measured in triplicates). As a
positive control, the yeast cells were exposed to the EC70
of estradiol in combination with the known ERα antagonist
RU 58688 [23]. For ERβ antagonism, the yeast cells were
exposed to the EC90 of estradiol in combination with R,R-
THC, a known antagonist on the ERβ [24].
In addition to the yeasts expressing the yEGFP reporter
gene in combination with either ERα or ERβ, a third yeast
strain was used that only contained the reporter gene but
not the vector with the ER. This yeast strain was used as a
negative control.
Results and discussion
Estrogenic activity of CPC fractions for ERα and ERβ
CPC fractionation of the licorice root extract resulted in 51
fractions (Fig. 1). After the 51
st fraction, no UV response was
observed anymore. Fractions F1 to 5, F6 to 21, and F22 to 51
comprised ∼25, ∼40, and ∼35% DW of the total extraction
yield, respectively (Electronic Supplementary Material
Table S1). Most fractions showed some estrogenicity on both
ERs, indicating the presence of phytoestrogens (Table 1).
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root extract fractionation by
CPC. Estrogenically active
fractions are indicated
Table 1 Estrogenic response of CPC fractions from the EA extract of licorice roots
3 μg/mL 10 μg/mL 0.3 μg/mL 1.0 μg/mL 3 μg/mL 10 μg/mL 0.3 μg/mL 1.0 μg/mL
Fr ERα ERα ERβ ERβ Fr ERα ERα ERβ ERβ
E2 100 100 F26
a 38.7 (±1.9) 93.7 (±6.1) 95.5 (±3.4) 151.3 (±15.1)
F1 ND ND 0.0 (±2.0) 0.0 (±2.0) F27
a 36.6 (±0.3) 90.8 (±2.1) 74.6 (±5.9) 176.5 (± 11.8)
F2 ND 1.1 (±1.2) 0.0 (±6.5) 0.0 (±4.9) F28
a 19.4 (±1.9) 48.2 (±2.7) 68.7 (±4.0) 104.4 (± 8.3)
F3 ND 4.9 (±0.7) 1.6 (±1.5) 0.0 (±4.5) F29
a 19.9 (±1.3) 23.0 (±3.9) 57.2 (±12.5) 93.5 (±0.6)
F4 ND 7.8 (±0.8) 13.4 (±5.0) 22.4 (±7.7) F30
a 23.8 (±2.7) 22.4 (±1.8) 57.3 (±1.1) 48.2 (±2.8)
F5 3.0 (±2.3) 7.8 (±0.3) 12.0 (±5.1) 19.5 (±2.2) F31 25.0 (±1.5) 34.2 (±1.9) 25.8 (±8.5) 40.5 (±17.8)
F6 ND ND ND ND F32
a 26.8 (±2.3) 34.5 (±2.0) 57.4 (±4.7) 47.4 (±10.7)
F7 17.1 (±3.0) 21.0 (±2.7) 21.4 (±5.6) 12.2 (±2.2)
b F33
a 32.0 (±1.4) 38.0 (±0.4) 50.2 (±9.5) 36.0 (±3.2)
F8 10.5 (±2.2) 21.8 (±6.3) 17.2 (±2.3) 58.3 (±3.4) F34 29.6 (±5.3) 44.9 (±1.3) 27.7 (±8.8) 46.1 (±5.2)
F9 13.3 (±1.5) 7.1 (±6.4) 37.8 (±10.0) 49.1 (±21.5) F35 30.8 (±3.1) 45.5 (±4.2) 43.6 (±7.6) 37.5 (±21.0)
F10 9.7 (±3.3) 9.3 (±2.0) 23.0 (±9.5) 57.3 (±12.9) F36 42.8 (±2.3) 42.9 (±6.5) 19.9 (±2.3) 45.3 (±2.5)
F11 ND ND 46.3 (±12.0) ND
b F37 13.6 (±1.6) 25.3 (±2.5) 24.8 (±2.6) 35.1 (±9.9)
F12 15.6 (±2.9) 15.7 (±3.2)
b 30.7 (±0.1) 77.2 (±7.3) F38 14.8 (±1.7) 28.8 (±0.5) 14.2 (±6.8) 30.8 (±15.4)
F13 ND ND 40.3 (±5.0) 2.4 (±4.9)
b F39 19.8 (±1.6) 32.4 (±2.6) 21.1 (±4.4) 45.6 (±14.7)
F14 4.8 (±4.7) ND 42.7 (±6.6) 73.3 (± 4.1) F40 25.6 (±4.3) 33.9 (±2.3) 26.5 (±5.5) 35.4 (±17.4)
F15 ND ND 28.4 (±7.1) 77.7 (± 1.8) F41
a 159.9 (±9.5) 186.9 (±15.0) 28.3 (±4.9) 34.9 (±13.5)
F16
a 74.8 (±4.0) 20.4 (±28.9)
b 40.7 (±1.0) 62.6 (± 2.1) F42 21.6 (±6.0) 26.2 (±2.2) 19.8 (±11.0) 53.8 (±25.5)
F17
a 109.1 (±2.3) 49.3 (±4.4)
b 36.7 (±9.5) 88.8 (± 8.2) F43 26.5 (±1.8) 24.7 (±4.3) 25.4 (±1.2) 38.9 (±20.0)
F18
a 105.3 (±6.2) 104.6 (±10.5)
b 57.1 (±9.4) 98.8 (± 15.1) F44 18.9 (±1.9) 24.6 (±1.5) 22.7 (±7.3) 33.8 (±12.2)
F19
a 89.1 (±4.2) 131.2 (±16.2) 48.3 (±4.6) 123.8 (±17.1) F45 20.9 (±1.5) 21.0 (±4.3) 19.6 (±3.4) 66.3 (±15.1)
F20
a 60.2 (±3.1) 140.5 (±10.7) 60.5 (±14.5) 116.7 (±14.3) F46 16.9 (±1.2) 20.5 (±3.2) 18.0 (±11.6) 73.8 (±7.3)
F21
a 71.9 (±8.4) 125.3 (±1.2) 45.2 (±3.8) 145.9 (±25.2) F47 21.2 (±2.9) 23.3 (±4.2) 31.0 (±5.1) 79.4 (±6.1)
F22
a 101.4 (±11.6) 134.1 (±2.7) 87.0 (±10.3) 144.4 (±10.7) F48 23.2 (±4.6) 21.7 (±2.4) 26.8 (±2.5) 49.1 (±17.8)
F23 16.0 (±0.9) 83.0 (±9.9) 26.3 (±8.7) 84.8 (±7.0) F49 26.4 (±0.6) 26.7 (±0.3) 16.5 (±3.0) 82.9 (±4.9)
F24
a 79.6 (±1.6) 156.3 (±14.4) 103.1 (±2.3) 159.3 (±23.1) F50 18.8 (±2.7) 16.7 (±3.2) 7.3 (±9.3) 41.3 (±3.1)
F25
a 44.2 (±5.7) 108.6 (±3.9) 97.9 (±10.6) 172.8 (±20.7) F51 22.0 (±3.2) 15.6 (±2.5) 18.8 (±2.7) 40.5 (±18.3)
The estrogenicity toward the ERα and the ERβ was measured at two concentrations. The activity was standardized to the maximum induced
response of 2 μM estradiol (100%). Values are the mean±SD (n=3). Estrogenic fractions are marked
Fr fraction, ND not detected (estrogenicity values were zero or slightly negative)
aEstrogenically active
bInhibited yeast growth due to cytotoxicity
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activates the ER at concentrations ≤10
4 times than that of
estradiol (E2)[ 25]. The EC50 value of E2 towards the ERα in
the yeast assay was determined to be 1.0–1.6×10
−9 M,
which corresponds to 2.7–4.4×10
−4 μg/mL. Therefore, only
CPC fractions giving a response above the EC50 at a dilution
below 3 μg/mL were indicated as active towards ERα in
Fig. 1. The application of this threshold value for the ERα
resulted in nine active fractions out of 51 (see Table 1).
The EC50 value of E2 towards the ERβ ranged from
1.1×10
−10 to 2.1×10
−10 M, corresponding to an EC50 of
3.2–5.9×10
−5 μg/mL. Therefore, only CPC fractions giving
a response above the EC50 at a dilution below 0.3 μg/mL
were indicated as active towards ERβ in Fig. 1.T h e
application of this threshold value for the ERβ resulted in
12 active fractions out of 51 (Table 1).
The screening for estrogenicity of the CPC fractions on
both receptor subtypes showed that the estrogenic response
of several fractions substantially exceeded the maximum
response of E2 (Table 1). This phenomenon has been
referred to as superinduction [26]. In our study, this
superinduction was observed with both receptors and
appeared more pronounced for ERβ. The mechanism that
leads to superinduction is not well understood but some-
times occurs with colored extracts. Such colored extracts
can disturb the fluorescent measurement, as, due to a
decrease of the pH during the exposure period, the color
can change as well.
To determine whether fractions gave an increased
fluorescent response as a result of acidification (change
of pH 5.0 to pH 2.9) of the culture medium due to yeast
growth, six representative fractions (F4, F13, F22, F27,
F30, and F44), with no, moderate, or high estrogenic
activity, were measured at different pH values in the
absence of yeast. No altered fluorescent signals were
observed compared with the blank, showing that the
observed superinduction was not related to altered
fluorescent signals due to a drop in pH.
In a next series of experiments, two subtype-selective
antagonists were used to determine whether the observed
estrogenic activities, including the superinduction, were ER-
mediated.First,RU58668(ERα-selective) [27]a n dR,R-THC
(ERβ-selective) [24] were tested in the yeast estrogen
bioassays to confirm their antagonistic properties. Co-
incubation of E2 and RU 58668 showed that 6×10
−6 MR U
58668 was able to decrease the E2-induced response of ERα
by ∼60% (Fig. 2A). RU 58668 itself showed a weak
agonistic activity of ∼12% in concentrations above 1×10
−5
Fig. 2 Transcription activation by ERα (A) and ERβ (B) in response
to E2 and subtype-selective antagonists RU58668 (ERα) and R,R-
THC (ERβ). The antagonistic activity of both receptor-specific
antagonists were assayed in the presence of the EC70 (0.8 nM) and
EC90 (0.2 nM) E2 for ERα and ERβ, respectively. Both graphs were
normalized to E2. The response of R,R-THC on ERβ for every
concentration was lower than the minimum response of E2. This was
corrected by normalizing the lowest concentration of R,R-THC to 0%.
Values are the mean±SD (n=3)
Table 2 Inhibition of estrogenic response of representative CPC









E2 100 60% 100 55%
F4 ND – 13.4 (±5.0) 70%
F13 ND – 40.3 (±5.0) 37%
F22 101.4 (±11.6) 52% 87.0 (±10.3) 34%
F27 36.6 (±0.3) 21% 74.6 (±5.9) 61%
F30 23.8 (±2.7) 21% 57.3 (±1.1) 48%
F44 18.9 (±1.9) 30% 22.7 (±7.3) 70%
Inhibition of the estrogenic response of six representative CPC
fractions were determined by co-incubation at 1 μg/mL with 6×
10
−6 M RU 58668 for the ERα and 1 μg/mL with 2×10
−8 M R,R-
THC for the ERβ. Values are the mean±SD (n=3)
ND not detected
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weak agonistic activity in the yeast estrogen bioassay with
ERα is not expected, as several other 11β-analogues of E2
were shown to be selective estrogen receptor modulators
(SERM) with both agonistic and antagonistic activity on the
ERα in the same yeast estrogen bioassay [23].
Co-incubation of E2 and R,R-THC showed that 2×10
−7
M R,R-THC was able to decrease the E2-induced response
of ERβ by ∼55% (Fig. 2B). Meyers and co-workers
reported an inhibition of ∼100% at similar concentrations
while using mammalian cell-based assays [24].
To determine whether the observed estrogenic responses
of the fractions were ER-mediated, selected fractions were
co-incubated with the subtype-selective antagonists. Besides,
the fractions were tested in the yeast strain that expresses no
estrogen receptor and only contains the reporter construct. In
all estrogen-active fractions, the responses were inhibited by
either RU 58668 or R,R-THC, and the fluorescence response
was reduced by up to 70%. This confirms that the estrogenic
responses caused by the fractions on both receptors were
ER-mediated (Table 2). Also, the controls with the yeast
strain expressing no ER confirmed that the observed
Fig. 3 Stabilizing effect of E2,
genistein, and several fractions
obtained from the licorice root
extract on the relative activity
measured after 6 and 24 h in the
ERβ assay. E2,2 × 1 0
−10 M
estradiol; Gen,2 × 1 0
−7 M
genistein; F4 to F44, licorice
root fractions obtained by CPC
measured at 0.3 μg/mL.
Asterisk, negative response
Table 3 Fractions generated by CPC fractionation and the presence of the main flavonoids in each fraction determined by ultra-high performance
LC-MS
Fraction 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Yield (mg) 110 141 97 136 108 126 211 345 254 156 66 176 157 115 37
Number of peaks 20 6 12 25 22 18 7 4 6 6 15 14 17 30 42
Of which are
Non-prenylated 3 1 2 4 2 1 0 0 0 0 0 1 2 4 9
Prenylated 17 5 10 21 20 17 7 4 6 6 15 13 15 26 33
Single-prenylated 13 3 7 9 6 8 4 1 2 3 11 11 13 18 22
Chain 7 2 4 6 4 5 2 0 1 2 7 5 9 13 21
Pyran 6 1 3 3 2 3 2 1 1 1 4 6 4 5 1
Double-prenylated 4 2 3 12 14 9 3 3 4 3 4 2 2 8 11
Characterization
Glabrene ++ ++ ++ ++ +
Glabrone + + ++ +
Glabridin + + ++ ++ + + +
Glabrol + ++ ++ + +
3′-OH-4′OMe-G
a + + ++ ++
4′-OMe-G
b + + ++ +
Hispaglabridin A + ++ ++
Hispaglabridin B ++ ++ +
a4′-O-methyl-glabridin
b3′-hydroxy-4′-O-methyl-glabridin
310 R. Simons et al.responses were ER-mediated, as no fluorescent signal was
observed for any of the fractions or E2.
Superinduction by stabilization of ER-mediated response
The phenomenon of superinduction has been previously
observed in several assay types and the superinduction
caused by genistein in human U2OS bone cells transfected
with the ERα and a luciferase reporter gene was intensively
investigated [26]. It was concluded that this superinduction
was caused by a post-translational stabilization of the firefly
luciferase reporter enzyme by genistein and not by
stabilization of the ERα. To verify the hypothesis that
superinduction in the yeast was caused by the stabilization
of the ER and/or the yEGFP, the yeast expressing ERβ was
co-incubated with E2, genistein, or the representative
fractions (F4, F13, F22, F27, F30, and F44) mentioned
before. The estrogenic responses were measured after 6 and
24 h (Fig. 3). After 6 h, both E2 and genistein showed the
maximum estrogenic response, but, as expected, the
estrogenic response of E2 completely disappeared after
24 h. Also, the response of genistein completely disap-
peared, whereas the estrogenic response of the fractions
was similar or even higher compared with their response
measured after 6 h. This strongly indicates that the
responses, including the superinduction, of the fractions
were stabilized. Our results do not allow speculation on
whether the ER, the yEGFP, or both proteins were
stabilized, but the observed estrogenic responses were
without doubt ER-mediated.
LC-MS characterization of licorice fractions
Because the estrogenic responses were ER-mediated, the
licorice fractions were subjected to characterization by LC-
MS. Fractions F6-21 contained the main flavonoids
previously annotated in the EA extract of licorice roots
(Table 3,F i g .4)[ 11]. These flavonoids have been
annotated based on UV and MS
n spectra and, if possible,
compared with spectra published in the literature. The
estrogenic activity of a number of active fractions (F20-
22,24-30,32-33,42) could not be traced back to individual
components (Electronic Supplementary Material Table S1).
Fig. 4 Main flavonoids identi-
fied in CPC fractions 6–21
obtained from the EA extract
of licorice root
Fig. 5 Antagonistic activity of glabridin on the estrogenic response in
the ERα yeast estrogen bioassay
Agonistic and antagonistic estrogens in licorice root 311Compositional analysis by LC-MS showed that the active
fractions were complex mixtures, indicating that further
purification of CPC fractions is prerequisite for the
identification of the estrogenic compounds. In most cases,
it was not possible to assign the identity of the predominant
peaks by UV and MS
n. Furthermore, in most fractions, the
majority of the compounds were prenylated, which might
suggest a correlation between prenylation and superinduc-
tion (Table 3, Electronic Supplementary Material Table S1).
Fractions F16-20, rich in glabrene, showed a predomi-
nant estrogenic activity on the ERα. This is in agreement
with the fact that glabrene is considered one of the principle
estrogenic components of licorice root. The estrogenic
potency of glabrene for both ER subtypes, however, has not
yet been established. Our results indicate that the glabrene-
rich fractions had a particularly high response towards
ERα. Whereas phytoestrogens generally have a more
pronounced affinity to the ERβ compared with the ERα,
the glabrene-rich fractions showed the opposite behavior,
similar to that of 8-prenyl naringenin [27].
In addition to glabrene, the estrogenic activity of licorice
rootsextracthasbeenascribedtothepresenceofglabridinand
its derivatives. Despite the abundance of glabridin in F11-15,
no significant estrogenic response on both ER subtypes was
observed. EC50 values of 5×10
−6 Mh a v eb e e nr e p o r t e df o r
glabridin, using different mammalian proliferation assays
[15–17]. Furthermore, several glabridin derivatives were
shown to be moderately estrogenic compared with glabridin
[14]. In our study, the pure reference standard of glabridin
did not exert any estrogenic response in a concentration
range of 1×10
−7 to 1×10
−4 M towards both ER subtypes
(data not shown). In concentrations above 1×10
−4 M,
glabridin was toxic to the yeast cells. Because glabridin
had been shown to interact with the ERs, and because it is
known that different ER-based bioassays can generate
different output, glabridin as well as the glabrene-rich
fraction F18 (due to the lack of a glabrene reference
standard) were tested for their antagonistic properties.
Antagonistic activity of glabridin and glabrene
Prenylation of isoflavonoids has been suggested to induce
antagonism towards the ERα [5, 7, 8]. The glabrene-rich
fraction F18 did not show antagonistic activity on both ER
subtypes (no further data shown) but increased the
estrogenic response upon co-exposure with E2, confirming
its agonistic character.
The reference standard of glabridin did not have
antagonistic properties towards the ERβ (data not shown)
but was shown to be an ERα-selective antagonist (Fig. 5).
At a concentration of 6×10
−6 M, glabridin was able to
inhibit the E2 response by ∼80% without being toxic
towards the yeast cells. The agonistic activity of glabridin
in the MCF-7 proliferation assay, in in vivo animal models,
and the ERα-selective antagonistic activity in the yeast
estrogen bioassay might imply that glabridin acts as a
SERM. The estrogenic activity of glabridin is similar to
kievitone and phaseollin, a prenyl-chain substituted iso-
flavanone and a pyran-ring substituted pterocarpan, respec-
tively. Both kievitone and phaseollin displayed agonistic
activity in the MCF-7 proliferation assay and in the human
HEK 293 transactivation assay but were antagonistic in the
MCF-7 colony-formation assay [28]. The assay-dependent
mode of action of glabridin has also been observed with
other compounds. For example, both tamoxifen and 4-
hydroxy-tamoxifen act as SERMs, displaying both estro-
genic and anti-estrogenic activities in mammalian breast
and endometrial cells, act as agonists in yeast estrogen
bioassays [27].
As mentioned before, LC-MS characterization showed
that fractions F6-15 were rich in glabridin derivatives.
These compounds share prenyl-substitution on the A-ring
with a pyran-ring (Table 3, Fig. 4). It will be worthwhile to
also test the purified glabridin derivatives for antagonistic
activity in the yeast estrogen bioassay.
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